FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016408145> ?p ?o ?g. }

• W2016408145 endingPage "452" @default.
• W2016408145 startingPage "445" @default.
• W2016408145 abstract "Aims Experimental studies have suggested that constant intravenous infusion would be preferable to conventional intermittent bolus administration of beta-lactam antibiotics for serious Gram-negative infections. Severe melioidosis (Burkholderia pseudomallei infection) carries a mortality of 40% despite treatment with high dose ceftazidime. The aim of this study was to measure the pharmacokinetic and pharmacodynamic effects of continuous infusion of ceftazidime vs intermittent bolus dosing in septicaemic melioidosis. Methods Patients with suspected septicaemic melioidosis were randomised to receive ceftazidime 40 mg kg−1 8 hourly by bolus injection or 4 mg kg−1 h−1 by constant infusion following a 12 mg kg−1 priming dose to perform estimation of pharmacokinetic and pharmacodynamic parameters. Results Of the 34 patients studied 16 (59%) died. Twenty patients had cultures positive for B. pseudomallei of whom 12 (60%) died. The median MIC90 of B. pseudomallei was 2 mg l−1, giving a target concentration CT, of 8 mg l−1. The median (range) estimated total apparent volume of distribution, systemic clearance and terminal elimination half-lives of ceftazidime were 0.468 (0.241–0.573) l kg−1, 0.058 (0.005–0.159) l kg−1 h−1 and 7.74 (1.95–44.71) h, respectively. Clearance of ceftazidime and creatinine clearance were correlated closely (r = 0.71; P < 0.001) and there was no evidence of significant nonrenal clearance. Conclusions Simulations based on these data and the ceftazidime sensitivity of the B. pseudomallei isolates indicated that administration by constant infusion would allow significant dose reduction and cost saving. With conventional 8 h intermittent dosing to patients with normal renal function, plasma ceftazidime concentrations could fall below the target concentration but this would be unlikely with a constant infusion. Correction for renal failure which is common in these patients is Clearance =k* creatinine clearance where k = 0.072. Calculation of a loading dose gives median (range) values of loading dose, DL of 3.7 mg kg−1 (1.9–4.6) and infusion rate I = 0.46 mg kg h−1 (0.04–1.3) (which equals 14.8 mg kg−1 day−1). A nomogram for adjustment in renal failure is given." @default.
• W2016408145 created "2016-06-24" @default.
• W2016408145 creator A5015402059 @default.
• W2016408145 creator A5017439674 @default.
• W2016408145 creator A5049241523 @default.
• W2016408145 creator A5050764672 @default.
• W2016408145 creator A5058967121 @default.
• W2016408145 creator A5060463156 @default.
• W2016408145 creator A5084217335 @default.
• W2016408145 creator A5085356323 @default.
• W2016408145 date "2000-05-01" @default.
• W2016408145 modified "2023-09-24" @default.
• W2016408145 title "Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion <i>vs</i> intermittent bolus injection in septicaemic melioidosis" @default.
• W2016408145 cites W1550111394 @default.
• W2016408145 cites W1807462308 @default.
• W2016408145 cites W1894308928 @default.
• W2016408145 cites W1968142908 @default.
• W2016408145 cites W1969084312 @default.
• W2016408145 cites W1973073979 @default.
• W2016408145 cites W1976679876 @default.
• W2016408145 cites W1977449346 @default.
• W2016408145 cites W1978999675 @default.
• W2016408145 cites W1980030251 @default.
• W2016408145 cites W1982986165 @default.
• W2016408145 cites W1990891055 @default.
• W2016408145 cites W1999279226 @default.
• W2016408145 cites W2005000232 @default.
• W2016408145 cites W2009720606 @default.
• W2016408145 cites W2021615041 @default.
• W2016408145 cites W2038074430 @default.
• W2016408145 cites W2060990271 @default.
• W2016408145 cites W2069808962 @default.
• W2016408145 cites W2071578083 @default.
• W2016408145 cites W2078251568 @default.
• W2016408145 cites W2089666099 @default.
• W2016408145 cites W2090430946 @default.
• W2016408145 cites W2101891378 @default.
• W2016408145 cites W2104759086 @default.
• W2016408145 cites W2114422486 @default.
• W2016408145 cites W2115779495 @default.
• W2016408145 cites W2119577847 @default.
• W2016408145 cites W2131171455 @default.
• W2016408145 cites W2132869689 @default.
• W2016408145 cites W2136028041 @default.
• W2016408145 cites W2137304822 @default.
• W2016408145 cites W2141173497 @default.
• W2016408145 cites W2154381036 @default.
• W2016408145 cites W2157336791 @default.
• W2016408145 cites W2158308518 @default.
• W2016408145 cites W2158502877 @default.
• W2016408145 cites W2166840599 @default.
• W2016408145 cites W2398156413 @default.
• W2016408145 cites W2408820156 @default.
• W2016408145 cites W2410400083 @default.
• W2016408145 cites W2416543865 @default.
• W2016408145 cites W2015920915 @default.
• W2016408145 doi "https://doi.org/10.1046/j.1365-2125.2000.00179.x" @default.
• W2016408145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10792202" @default.
• W2016408145 hasPublicationYear "2000" @default.
• W2016408145 type Work @default.
• W2016408145 sameAs 2016408145 @default.
• W2016408145 citedByCount "21" @default.
• W2016408145 countsByYear W20164081452013 @default.
• W2016408145 countsByYear W20164081452021 @default.
• W2016408145 countsByYear W20164081452023 @default.
• W2016408145 crossrefType "journal-article" @default.
• W2016408145 hasAuthorship W2016408145A5015402059 @default.
• W2016408145 hasAuthorship W2016408145A5017439674 @default.
• W2016408145 hasAuthorship W2016408145A5049241523 @default.
• W2016408145 hasAuthorship W2016408145A5050764672 @default.
• W2016408145 hasAuthorship W2016408145A5058967121 @default.
• W2016408145 hasAuthorship W2016408145A5060463156 @default.
• W2016408145 hasAuthorship W2016408145A5084217335 @default.
• W2016408145 hasAuthorship W2016408145A5085356323 @default.
• W2016408145 hasBestOaLocation W20164081452 @default.
• W2016408145 hasConcept C111113717 @default.
• W2016408145 hasConcept C112705442 @default.
• W2016408145 hasConcept C126322002 @default.
• W2016408145 hasConcept C139254425 @default.
• W2016408145 hasConcept C142724271 @default.
• W2016408145 hasConcept C2776968632 @default.
• W2016408145 hasConcept C2777288759 @default.
• W2016408145 hasConcept C2777637488 @default.
• W2016408145 hasConcept C2779110727 @default.
• W2016408145 hasConcept C2779775996 @default.
• W2016408145 hasConcept C3019249092 @default.
• W2016408145 hasConcept C42219234 @default.
• W2016408145 hasConcept C43376680 @default.
• W2016408145 hasConcept C501593827 @default.
• W2016408145 hasConcept C523546767 @default.
• W2016408145 hasConcept C54355233 @default.
• W2016408145 hasConcept C71924100 @default.
• W2016408145 hasConcept C86803240 @default.
• W2016408145 hasConcept C89423630 @default.
• W2016408145 hasConcept C98274493 @default.
• W2016408145 hasConceptScore W2016408145C111113717 @default.
• W2016408145 hasConceptScore W2016408145C112705442 @default.
• W2016408145 hasConceptScore W2016408145C126322002 @default.

• next